Research publications from Maverex
We share peer-reviewed research publications across oncology, cardiovascular, infectious disease and much more.
Browse or search our latest publications.
Reducing carbon footprint by switching to reusable soft mist inhalers
Janson C, Platz JH, Soulard S, Langham S, Nicholson L, Hartgers-Gubbels ES. Reducing carbon footprint by switching to reusable soft mist inhalers. ERJ Open Res 2023;9(3):00543-2022.
Durability of vaccine-induced and natural immunity against COVID-19: a narrative review
Pooley N, Abdool Karim SS, Combadière B, Ooi EE, Harris RC, El Guerche Seblain C, et al. Durability of vaccine-induced and natural immunity against COVID-19: a narrative review. Infect Dis Ther 2023:1-21.
Cost–consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK
Wright A, Vioix H, de Silva S, Langham S, Cook J, Capstick T, et al. Cost–consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK. BMJ Open 2022;12(6):e059158.
Costs and clinical consequences of compliance with COPD GOLD recommendations or national guidelines compared with current clinical practice in Belgium, Germany, Sweden, and the United States
Sethi S, Wright A, Hartgers-Gubbels E, Hechtner M, Clark B, Wright C, et al. Costs and clinical consequences of compliance with COPD GOLD recommendations or national guidelines compared with current clinical practice in Belgium, Germany, Sweden, and the United States. Int J Chron Obstruct Pulmon Dis 2022;17:2149-2160.
Rapid evidence publication in the COVID-19 era: impact on study quality and study identification
Wright C, Misso K, Green R, Marjenberg Z. Rapid evidence publication in the COVID-19 era: impact on study quality and study identification (SA43). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
Reusable soft mist inhalers have an improved carbon footprint compared with dry powder inhalers and pressurised metered-dose inhalers
Janson C, Hernando Platz J, Soulard S, Langham S, Nicholson L, Hartgers-Gubbels E. Reusable soft mist inhalers have an improved carbon footprint compared with dry powder inhalers and pressurised metered-dose inhalers (HSD2). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
Treatment with dual and triple therapy in chronic obstructive pulmonary disease in line with current guidelines reduces the carbon footprint
Janson C, Hernando Platz J, Soulard S, Langham S, Nicholson L, Hartgers-Gubbels E. Treatment with dual and triple therapy in chronic obstructive pulmonary disease in line with current guidelines reduces the carbon footprint (MT40). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis
Müllerová H, Marshall J, de Nigris E, Varghese P, Pooley N, Embleton N, et al. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Ther Adv Respir Dis 2022;16:17534666221113647.
The burden of progressive-fibrosing interstitial lung diseases
Cottin V, Teague R, Nicholson L, Langham S, Baldwin M. The burden of progressive-fibrosing interstitial lung diseases. Front Med 2022;9:7999912
